A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs PRN 1008 (Primary) ; Prednisone
- Indications Pemphigus; Pemphigus vulgaris
- Focus Registrational; Therapeutic Use
- Acronyms PEGASUS
- Sponsors Principia Biopharma
- 10 Oct 2019 Dr. Murrell from New South Wales in Sydney, Australia, is the Principal Investigator of the this trial.
- 19 Mar 2019 According to a Principia Biopharma media release, data from the trial anticipated in the first half of 2022.
- 30 Nov 2018 Status changed from planning to recruiting.